Significant Ownership of BridgeBio Pharma LLC

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for BridgeBio Pharma LLC focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Neil Kumar - Neil Kumar, Chief Executive Officer
Manager location
Palo Alto, CA

Follow Filing Activity

Follow BridgeBio Pharma LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of BridgeBio Pharma LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HLXB BridgeBio Oncology Therapeutics, Inc. Common Stock, $0.0001 par value 18% 13,878,554 BridgeBio Pharma LLC 11 Aug 2025

Schedules 13D/G Reported by BridgeBio Pharma LLC:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .